SPARC incorporates subsidiary ‘Genokine Biotech’
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Subscribe To Our Newsletter & Stay Updated